A/Prof Mikaël Martino (Monash University) is a renowned innovator in regenerative medicine, known for translating ground-breaking technologies into impactful solutions with the potential to reshape tissue repair and improve patient outcomes.
With a strong track record of securing seed funding and fostering international collaborations, A/Prof Martino is committed to driving advancements in the field through his patented technologies and biotech ventures.
Myostellar, a biotech company led by A/Prof Martino and Prof Peter Currie from the Australian Regenerative Medicine Institute, develops much-needed new therapies to treat
debilitating muscular dystrophies.
An exciting discovery made by the researchers, published in Nature in 2021, was the catalyst for the startup, which is focused on developing a novel, first-in-class therapy for stimulating skeletal muscle regeneration with minimal fibrosis.
A/Prof Martino is also the co-founder of protein-engineering spin-out Orio Therapeutics, which aims to spearhead the development of new drug-delivery technology that enables better therapeutic effects at consistent and lower doses.
Read more case studies on EMBL Australia group leaders in our Impact Report.